Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S P Ball

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
American Heart Journal|January 1, 1991
Recombinant tissue-type plasminogen activator: current concepts and guidelines for clinical use in acute myocardial infarction. Part IR C Becker, J M Corrao, R Harrington, et al.
Catheterization and Cardiovascular Diagnosis|November 1, 1991
Angiographically documented thrombotic coronary artery occlusion secondary to mild nonpenetrating thoracic traumaS J Voyce, S P Ball, J M Gore, et al.
Journal of Thrombosis and Thrombolysis|March 23, 2000
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralizationF A Spencer, S P Ball, Q Zhang, et al.
Eye (London, England)|January 1, 1991
Lens epithelial cells adhere less to HEMA than to PMMA intraocular lensesR C Humphry, S P Ball, J E Brammall, et al.
The American Journal of Cardiology|June 1, 1987
Peak creatine kinase as a measure of effectiveness of thrombolytic therapy in acute myocardial infarctionJ M Gore, R Roberts, S P Ball, et al.
Annals of Human Genetics|July 1, 1991
The human chromosome 19 linkage group FUT1 (H), FUT2 (SE), LE, LU, PEPD, C3, APOC2, D19S7 and D19S9S P Ball, N Tongue, A Gibaud, et al.
Journal of the American College of Cardiology|October 16, 1999
Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potentialR C Becker, F A Spencer, Y Li, et al.
Clinical Research|February 1, 1991
The consent process in the Thrombolysis in Myocardial Infarction (TIMI--phase I) trialI S Ockene, J Miner, T A Shannon, et al.
Human Mutation|January 1, 1993
No C1840 to T mutation in RYR1 in malignant hyperthermiaJ L Hall-Curran, A D Stewart, S P Ball, et al.
The American Journal of Cardiology|August 1, 1988
Impact of thrombolytic therapy on left ventricular mural thrombi in acute myocardial infarctionA C Held, J M Gore, J Paraskos, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
American Heart Journal|January 1, 1991
Recombinant tissue-type plasminogen activator: current concepts and guidelines for clinical use in acute myocardial infarction. Part IR C Becker, J M Corrao, R Harrington, et al.
Catheterization and Cardiovascular Diagnosis|November 1, 1991
Angiographically documented thrombotic coronary artery occlusion secondary to mild nonpenetrating thoracic traumaS J Voyce, S P Ball, J M Gore, et al.
Journal of Thrombosis and Thrombolysis|March 23, 2000
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralizationF A Spencer, S P Ball, Q Zhang, et al.
Eye (London, England)|January 1, 1991
Lens epithelial cells adhere less to HEMA than to PMMA intraocular lensesR C Humphry, S P Ball, J E Brammall, et al.
The American Journal of Cardiology|June 1, 1987
Peak creatine kinase as a measure of effectiveness of thrombolytic therapy in acute myocardial infarctionJ M Gore, R Roberts, S P Ball, et al.
Annals of Human Genetics|July 1, 1991
The human chromosome 19 linkage group FUT1 (H), FUT2 (SE), LE, LU, PEPD, C3, APOC2, D19S7 and D19S9S P Ball, N Tongue, A Gibaud, et al.
Journal of the American College of Cardiology|October 16, 1999
Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potentialR C Becker, F A Spencer, Y Li, et al.
Clinical Research|February 1, 1991
The consent process in the Thrombolysis in Myocardial Infarction (TIMI--phase I) trialI S Ockene, J Miner, T A Shannon, et al.
Human Mutation|January 1, 1993
No C1840 to T mutation in RYR1 in malignant hyperthermiaJ L Hall-Curran, A D Stewart, S P Ball, et al.
The American Journal of Cardiology|August 1, 1988
Impact of thrombolytic therapy on left ventricular mural thrombi in acute myocardial infarctionA C Held, J M Gore, J Paraskos, et al.
Pageof 3